WEIGHT LOSS TREATMENTS
Beware of weight loss medications; they can make you go blind
A recent study conducted by researchers at Massachusetts Eye and Ear hospital has found a significant link between popular weight loss drugs containing semaglutide and an increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare condition causing sudden vision loss in one eye. The study, published in JAMA Ophthalmology, revealed that obese patients using these medications were over seven times more likely to develop NAION, while diabetic patients faced more than four times the risk.
Waiting for a wonder drug? The weight just got longer
Eli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the drug in India in 2025, pending supply. The SEC recommends approval for pre-filled pens and vials, contingent on a phase-IV trial. The Drug Controller General of India will finalize the decision.
Headphone culture: Why Alka Yagnik’s advice should not fall on deaf ears
In the wake of the Bollywood singer’s revelation that she was diagnosed with sudden hearing loss, doctors caution against listening to high-decibel music using headphones for a long duration
Diabetes management made easier: Your guide to a healthier lifestyle
Proactively collaborating with healthcare professionals for personalized strategies enhances diabetes management, leading to improved overall well-being and better health outcomes.
Biocon seeks partner to test generic Wegovy, Ozempic in China
India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find a partner for the trials on over 500 patients in China, citing the substantial investment required. The move comes ahead of the patent protection expiry on key ingredients in the drugs in 2026.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
- Go To Page 1
Ozempic: Bengaluru is the secret ingredient behind the wonder weight loss drugs' success
Novo Nordisk's India team played a pivotal role in the success of Ozempic, a semaglutide-based drug for diabetes and weight management. The Bengaluru-based Global Business Services unit collaborated on clinical trials and biostatistics. Despite global demand, Ozempic's availability in India remains uncertain due to supply challenges, with significant hiring planned to bolster Novo Nordisk's workforce in India.
Shedding light on weight loss struggles among diabetics
Diabetes cases in India are rising, with 101 million individuals affected according to ICMR- INDIAB data. The International Diabetes Federation projects a 46% increase in global diabetes cases by 2045.
Exercise & diet play key role in enhancing survival for cancer patients
The mainstays of cancer treatment remain surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy and hormone therapy. But there are other treatments and strategies - "adjunct" or supportive cancer care - that can have a powerful impact on a patient's quality of life, survival and experience during cancer treatment.
Uphill Battle: Navigating the Complexities of Diabetes Management
Managing type 2 diabetes involves crucial lifestyle changes for blood sugar control, mental health support, weight management, nutrition therapy, stress management, physical activity, and glucose regulation.
Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India
Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife for my appearance,” says Rajput. The drugs — Wegovy and Ozempic — which have the same ingredient, semaglutide, are all the rage ever since entrepreneur Elon Musk tweeted about it.
‘Obese people should opt for a structured programme of diet, exercise & medication’
"Nothing comes without a downside. These molecules do produce significant nausea and vomiting in some people — to the extent that they have to discontinue the medication. Some may develop diarrhoea, some may have severe constipation. Others may not like the way they lose weight—they may feel very shrunken or their face may seem very thinned out. That’s another sort of downside," says Dr Ambrish Mithal, chairman, endocrinology & diabetes, Max Healthcare, Delhi.
Eli Lilly in advanced clinical trials for its weight-loss pill
Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with Type 2 diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron.
Novo Nordisk to buy Cardior Pharma for up to $1 billion
Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.
Kate Middleton and King Charles's cancer diagnosis: Understanding cancer, treatment plans and what experts say
Princess Catherine revealed a cancer diagnosis in a video message, disclosing she was undergoing "preventative chemotherapy" after major surgery. This follows King Charles III's cancer diagnosis, which led to him starting "regular treatments" while continuing his role as head of state. Cancer is a leading global cause of death, with early detection crucial for better outcomes. Treatments include surgery, chemotherapy, and radiotherapy, with advancements improving survival rates. Catherine's disclosure highlights the importance of early detection and ongoing research in fighting cancer.
Congress told me to lose 10 kg weight to meet Rahul Gandhi, alleges former youth Congress chief
Zeeshan Siddique, former Mumbai Youth Congress president, claimed he was told to lose weight before meeting Rahul Gandhi during the 'Bharat Jodo Yatra' in Maharashtra. He criticized the mistreatment of minority leaders within Congress. Siddique resigned and joined the Ajit Pawar-led NCP. He voiced concerns about the Congress party's alliance with Uddhav Thackeray's Shiv Sena faction.
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddy's, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.
Anti-obesity drug market gaining traction in India
According to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five years, the market has grown at 32% CAGR to 474 crore in January 2024.
Lilly rides wave of weight-loss drug demand, working to expand capacity
Shares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capitalization and most valuable healthcare company.
Budget Ozempic: Know about this weight loss trend on Tik Tok and its associated risks
In recent years, Ozempic, the winning diabetic drug is very much in demand, taking the world of weight loss by storm. Here's everything to know more
Weighty issues: A healthy muscle mass can be a life & death matter for cancer patients
Despite the significance of cachexia for cancer patients, there has been very little progress in treating the condition.
What other health conditions might weight-loss drugs treat?
New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.
Weight-loss drugs: Who, and what, are they good for?
The new drugs are known as GLP-1 agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15% to 20% of their body weight, depending on the drug. Nearly 120 million American adults could be eligible for treatment, while Novo says its target market is more than 760 million people with obesity worldwide.
What is Ozempic? Exploring Hollywood's viral obsession and its weight loss appeal
Hollywood’s caught onto Ozempic! Initially for Type 2 diabetes, the FDA-approved drug, semaglutide (marketed as Ozempic), has become a celeb-driven weight loss trend. Amid shortages and denials, stars like Amy Schumer openly discuss its effects. Concerns arise about "Ozempic face" – facial sagging due to rapid weight loss. Stars have mixed thoughts – cautionary or critical – sparking a debate on bodies and fame's influence.
How well-off Brits still buy Ozempic online for weight loss
The demand for the diabetes drug Ozempic, known for its weight-loss effects, has led to shortages in countries like Britain and the United States. A contrast in access reveals that those with means can purchase it online for weight loss, despite government restrictions. The shortage, caused by overwhelming demand, is impacting diabetes patients dependent on the NHS, jeopardizing their health.
What's behind the scramble for semaglutide?
The global demand for the diabetes medicine Ozempic, containing semaglutide, is causing shortages in several countries due to its off-label use for weight loss. Novo Nordisk, the manufacturer, cites ongoing supply constraints. The company plans a $6 billion investment by 2029 to boost production. Britain and Belgium have restricted prescriptions for weight loss, and Germany considers banning exports due to affordability-driven demand.
Fake weight loss injections leave people in comas, urgent safety alert issued
Fake weight loss injections, falsely marketed as Ozempic or Saxenda, have triggered significant safety alarms in the United Kingdom. Authorities are cautioning the public about the substantial risks associated with these counterfeit products, as several individuals have encountered life-threatening medical complications.
Corporate America weighs risks of the Ozempic effect
U.S. companies in various sectors, including food and beverage, medical devices, and dialysis services, are facing questions from investors regarding the impact of weight-loss drugs on their future sales. Companies like Conagra and Walmart are considering potential changes in portion sizes and expect increased revenues from health and wellness products due to the popularity of these drugs. On the other hand, companies like PepsiCo and Abbott Laboratories do not anticipate a significant impact on their sales.
Dr Reddy's gears up for weight loss drug study
Dr Reddy's Laboratories has received approval from India's drug regulatory authority to conduct a bioequivalence study for the weight loss drug Semaglutide. The company had sought a waiver for the study and a Phase III clinical trial, but the SEC recommended conducting the study. If all goes well, the drug could be launched within a year.
Load More
